Last edition
News about "Glenmark Pharma introduces 400 mg version of FabiF"
Glenmark Pharma introduces 400 mg version of FabiFlu for COVID-19 treatment
Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, announced that it will introduce a 400 mg version of oral antiviral FabiFlu, for the treatment of mild to moderate COVID-19 in India. The higher strength will improve patient compliance and experience, by effectively reducing the number of tablets that patients
Glenmark Pharma Introduces 400 Mg Version Of FabiF | 06/08/2020 | By Darshana | 446
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy